Maravai LifeSciences Holdings, Inc. Cash and Restricted Cash
Maravai LifeSciences Holdings, Inc. (MRVI) had Cash and Restricted Cash of $70.58 million as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-07
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $70.58M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $165.92M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $216.89M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $243.57M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $70.58M 10-Q · filed 2026-08-07 |
| 2026-03-31 | $165.92M 10-Q · filed 2026-05-08 |
| 2025-12-31 | $216.89M 10-Q · filed 2026-08-07 |
| 2025-09-30 | $243.57M 10-Q · filed 2025-11-07 |
| 2025-06-30 | $269.91M 10-Q · filed 2026-08-07 |
| 2025-03-31 | $285.05M 10-Q · filed 2026-05-08 |
| 2024-12-31 | $322.40M 10-Q · filed 2026-08-07 |
| 2024-09-30 | $578.16M 10-Q · filed 2025-11-07 |
| 2024-06-30 | $573.17M 10-Q · filed 2025-08-11 |
| 2024-03-31 | $561.69M 10-Q · filed 2025-05-12 |
| 2023-12-31 | $574.96M 10-K · filed 2026-02-26 |
| 2023-09-30 | $579.61M 10-Q · filed 2024-11-12 |
| 2023-06-30 | $580.18M 10-Q · filed 2024-08-08 |
| 2023-03-31 | $628.27M 10-Q · filed 2024-05-09 |
| 2022-12-31 | $632.14M 10-K · filed 2026-02-26 |
| 2022-09-30 | $617.45M 10-Q · filed 2023-11-08 |
| 2022-06-30 | $550.68M 10-Q · filed 2023-08-08 |
| 2022-03-31 | $431.47M 10-Q · filed 2023-05-09 |
| 2021-12-31 | $551.27M 10-K · filed 2025-03-18 |
| 2021-09-30 | $547.90M 10-Q · filed 2022-11-04 |
| 2021-06-30 | $374.71M 10-Q · filed 2022-08-05 |
| 2021-03-31 | $247.68M 10-Q · filed 2022-05-06 |
| 2020-12-31 | $236.18M 10-K · filed 2024-02-29 |
| 2020-09-30 | $124.88M 10-Q · filed 2021-11-15 |
| 2020-06-30 | $84.46M 10-Q · filed 2021-08-11 |
| 2020-03-31 | $76.75M 10-Q · filed 2021-05-12 |
| 2019-12-31 | $24.70M 10-K · filed 2023-02-28 |
| 2018-12-31 | $21.87M 10-K · filed 2022-03-01 |